Cordis Endovascular Systems (US) files patent suit against Target:
This article was originally published in Clinica
Executive Summary
Cordis Endovascular Systems (US) has filed suit in the San Jose District Court against Target Therapeutics (US), alleging infringement of its patents on microcatheters, guidewires and guiding catheters used to diagnose and treat disorders of the brain, liver and other internal organs (US Patent Nos 4,596,563; 4,846,186; and 5,171,232). Target products alleged to infringe the patents, which were filed in March 1984, include lines of Tracker and FasTracker microcatheters, Dasher guidewires and FasGuide guiding catheters.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.